See the DrugPatentWatch profile for Gazyva
Gazyva can cause several side effects, with the most common being infusion-related reactions [1][2]. These reactions may include symptoms such as fever, chills, rash, and difficulty breathing [1].
What are Gazyva's most serious side effects?
Serious side effects associated with Gazyva include severe infusion-related reactions, which can be life-threatening [1]. Other significant risks involve tumor lysis syndrome (TLS), a condition where cancer cells release their contents into the bloodstream rapidly, potentially leading to kidney failure, heart rhythm abnormalities, or seizures [1][3]. Gazyva can also cause a decrease in blood cell counts, increasing the risk of infection, bleeding, or anemia [1]. In some cases, it may lead to bowel problems, such as obstruction or perforation [1].
How are Gazyva infusion reactions managed?
Infusion reactions are typically managed by slowing down or stopping the infusion and administering supportive care, such as fever-reducing or anti-allergy medications [1]. Healthcare providers monitor patients closely during and after infusions for any signs of such reactions [1].
What are the long-term risks of Gazyva treatment?
Long-term risks can include the potential for developing other cancers [1]. There is also a risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection [1]. Patients may also experience reactivation of hepatitis B virus if they have been previously infected [1][4].
What blood count changes can Gazyva cause?
Gazyva can cause neutropenia (low white blood cell count), thrombocytopenia (low platelet count), and anemia (low red blood cell count) [1]. These changes can increase the risk of infections, bleeding, and fatigue [1].
Can Gazyva affect the bowel?
Yes, Gazyva can lead to bowel-related complications, including obstruction or perforation, which are serious conditions [1].
What is tumor lysis syndrome in the context of Gazyva?
Tumor lysis syndrome is a complication that can occur when cancer cells are rapidly destroyed, releasing their contents into the bloodstream. This can cause dangerous changes in electrolyte levels, potentially leading to kidney failure, heart rhythm problems, and seizures [1][3].
What should patients discuss with their doctor before starting Gazyva?
Before starting Gazyva, patients should discuss their complete medical history, including any history of hepatitis B infection, with their doctor [1][4]. It is also important to inform the doctor about any current medications or pre-existing conditions [1].
How is Gazyva administered?
Gazyva is administered intravenously, meaning it is given through a vein [1]. The infusion is typically given in a healthcare setting by a trained medical professional [1].
What is the mechanism of action of Gazyva?
Gazyva is a monoclonal antibody that targets the CD20 protein found on the surface of B-cells, a type of white blood cell [1][5]. It works by binding to CD20 and causing the destruction of these B-cells, including cancerous B-cells [1][5].
How does Gazyva compare to other treatments for similar cancers?
Gazyva is often used in combination with chemotherapy regimens. For example, it is approved for certain types of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) [1][2]. Its efficacy and side effect profile are considered in the context of these combination therapies.
What is the regulatory status of Gazyva?
Gazyva is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for specific hematologic malignancies [1][2].
What patient populations is Gazyva indicated for?
Gazyva is indicated for the treatment of certain types of non-Hodgkin lymphoma, specifically relapsed or refractory follicular lymphoma, and for previously untreated follicular lymphoma in combination with chemotherapy [2]. It is also used for chronic lymphocytic leukemia (CLL) in combination with chemotherapy [1].
Are there any contraindications for Gazyva use?
Gazyva should not be used in patients with known hypersensitivity to obinutuzumab or any of its components [1].
---
Sources:
1. https://www.gazyvahcp.com/hcp/important-safety-information/
2. https://www.roche.com/media/releases/2013-11-01.htm
3. https://www.cancer.gov/publications/dictionaries/cancer-drug-terms/tumor-lysis-syndrome
4. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients/medwatch-safety-alerts-drugs-products-and-therapies/medwatch-2017-drug-safety-communications/medwatch-2017-drug-safety-communication-fda-advises-healthcare-professionals-and-patients-about-need
5. https://www.gene.com/medicines/gazyva/how-it-works